12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Rempex Pharmaceuticals preclinical data

In a multi-drug resistant isolate panel of Enterobacteriaceae, the minimum inhibitory concentration with antimicrobial activity against 90% of the isolates (MIC90) was 0.5 µg/mL for Carbavance vs....

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >